# Backtesting Clinical Trials Indicator

## Companies to Test

Company | BriefTitle | StudyFirstPostDate | StartDate | CompletionDate | OverallStatus | Price 1-day PreStartDate | Price 3-day PostStartDate | PriceIncrease
------- | ---------- | ------------------ | -------------- | ------------- | ------------------------ | ------------------------- | ------------- | -------------
Incannex Healthcare Inc. | Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis | 12/07/2023 | 22/11/2023 | 12/2024 | Recruiting | 3.43 | 4.32 | 20.60%
Incannex Healthcare Inc. | RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA | 24/11/2023 | 01/2024 | 12/2026 | Not Yet Recruiting | NA | NA | NA
Incannex Healthcare Inc. | Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs | 12/05/2023 | 08/09/2023 | 06/2024 | Recruiting | 0.07 | 0.094 | 25.53%
Morphic Holding Inc. | A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC | 10/11/2022 | 31/10/2022 | 07/2025 | Recruiting | 29.08 | 27.43 | -5.67%
Morphic Holding Inc. | A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease | 26/01/2024 | 03/2024 | 03/2028 | Not Yet Recruiting | 

### Python Table

Company Name | NCTId | OverallStatus | StudyFirstPostDate | StartDate | CompletionDate
------------ | ----- | ------------- | ------------------ | --------- | --------------




